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A B S T R A C T
Risk prediction for psychosis has advanced to the stage at which it could feasibly become a clinical reality.
Neuroimaging biomarkers play a central role in many risk prediction models. Using such models to predict the
likelihood of transition to psychosis in individuals known to be at high risk has the potential to meaningfully
improve outcomes, principally through facilitating early intervention. However, this compelling benefit must be
evaluated in light of the broader ethical ramifications of this prospective development in clinical practice. This
paper advances ethical discussion in the field in two ways: firstly, through in-depth consideration of the dis-
tinctive implications of the clinical application of predictive tools; and, secondly, by evaluating the manner in
which newer predictive models incorporating neuroimaging alter the ethical landscape. We outline the current
state of the science of predictive testing for psychosis, with a particular focus on emerging neuroimaging bio-
markers. We then proceed to ethical analysis employing the four principles of biomedical ethics as a conceptual
framework. We conclude with a call for scientific advancement to proceed in tandem with ethical consideration,
informed by empirical study of the views of high risk individuals and their families. This collaborative approach
will help ensure that predictive testing progresses in an ethically acceptable manner that minimizes potential
adverse effects and maximizes meaningful benefits for those at high risk of psychosis.
1. Introduction
Risk prediction for psychosis has advanced to the stage at which it
could feasibly become a clinical reality. Neuroimaging biomarkers play
a central role in many risk prediction models. Using such models to
predict the likelihood of transition to psychosis in individuals known to
be at high risk has the potential to meaningfully improve outcomes,
principally through facilitating early intervention (Correll et al., 2018).
In addition, knowledge of risk status can enable individuals to minimize
modifiable risk factors, better understand subthreshold psychotic ex-
periences, access self-education and peer support, and make future
plans in case of illness onset. In time, it may be possible to intervene to
avert transition to psychosis, however, at present the evidence base for
preventative interventions remains inconclusive (S Tognin et al., 2019).
These potential gains are compelling; however they must be evaluated
in light of the broader ethical ramifications of this prospective devel-
opment in clinical practice. This paper advances ethical discussion in
the field in two ways: firstly, through in-depth consideration of the
distinctive implications of the clinical application of predictive tools;
and, secondly, by evaluating the manner in which newer predictive
models incorporating neuroimaging alter the ethical landscape. We
initially outline the current state of the science of predictive testing for
psychosis, with a particular focus on emerging neuroimaging bio-
markers, then proceed to ethical analysis employing the four principles
of biomedical ethics as a conceptual framework (Beauchamp and
Childress, 2001). We conclude with a call for scientific advancement to
proceed in tandem with ethical consideration, informed by empirical
study of the views of high risk individuals and their families. This
collaborative approach will help ensure that predictive testing pro-
gresses in an ethically acceptable manner that minimizes potential
adverse effects and maximizes meaningful benefits for those at high risk
of psychosis.
2. Current prediction methods
2.1. Clinical and familial high risk groups
The last three decades have witnessed considerable progress in the
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application of biomarkers, demographic risk factors, and symptom
profiles to predict the development of psychosis. Current research
models focus on risk prediction within high risk groups, a narrowing of
inclusion criteria necessitated by the relatively low incidence of psy-
chosis within the general population (Yung and Nelson, 2013). High
risk individuals are categorized into ‘clinical high risk’ (also known as
‘ultra high risk’), and ‘familial high risk’. Clinical high risk groups
comprise of those with low grade ‘pre-psychotic’ symptoms, variously
described as ‘attenuated psychotic symptoms’ or the ‘at risk mental
state’. These symptoms do not meet diagnostic criteria for schizo-
phrenia or other psychotic disorders, either due to their non-specific
nature or short-lived course (Fusar-Poli et al., 2013). Subthreshold
symptoms have been repeatedly shown to be independently predictive
of transition to psychosis at rates of up to 39% over a two-year period
(Fusar-Poli et al., 2016). Admittedly, heterogeneity exists between
studies in the definition of transition to psychosis, largely due to var-
iation in diagnostic criteria, thus limiting the generalizability of results
(McGorry et al., 2018). However, ongoing large consortia-based pro-
jects (most notably PRONIA and PSYSCAN, which include multiple
global sites) aim to redress this issue (S Tognin et al., 2019;
Koutsouleris et al., 2018). Familial high risk groups consist of in-
dividuals at presumed elevated genetic risk, traditionally determined
through degree of relatedness to an affected individual
(Johnstone et al., 2002; Erlenmeyer-Kimling et al., 1997;
Jørgensen et al., 1987). Notably, there is a degree of crossover between
clinical and familial high risk groups (Smieskova et al., 2013). Funda-
mentally, it is possible to reliably identify a group of, generally, young
individuals who present with overlapping clinical and/or genetic risk
markers and are thus at elevated risk of developing psychosis
(Johnstone et al., 2002; Fusar-Poli et al., 2012). Recent advances em-
ploy machine learning in conjunction with neuroimaging and genetic
biomarkers, and clinical risk factors to quantify psychosis susceptibility
with increased accuracy.
2.2. Neuroimaging biomarkers
A number of key neuroimaging biomarkers have been consistently
found to predict transition to psychosis. In keeping with the theory of
psychosis (schizophrenia in particular) as a disorder of the developing
brain, characteristic changes appear dynamic over time
(Takahashi et al., 2009; Cannon et al., 2015; Sun et al., 2009). In fact, it
is the evolving nature of many gray matter abnormalities that is most
predictive of transition to psychosis, rather than any abnormality in
isolation (Bois et al., 2015).
Reduced gray matter density within cortical regions including the
temporal lobes, frontal lobes, cingulate gyri, and hippocampi has re-
peatedly demonstrated predictive properties for psychosis (Fusar-
Poli et al., 2012). In addition, meta-analysis of studies utilizing voxel-
based morphometry revealed reduced gray matter volume in the insula,
cerebellum, anterior cingulate cortex, and the prefrontal cortex as being
predictive of onward transition to psychosis (Smieskova et al., 2010).
Furthermore, there is a growing body of evidence indicating the
presence of neurophysiological functional changes in individuals at
high risk of psychosis (Lin et al., 2019). A small number of studies
utilizing fMRI in high risk individuals have found significant differences
in brain regional activation during neurocognitive task performance,
and variation in functional connectivity in the resting state at baseline
in those who subsequently transition to psychosis compared with those
who do not (Whalley et al., 2006; Sabb et al., 2010; Anticevic et al.,
2015). In addition, a small number of PET studies of high risk cohorts
demonstrate increased presynaptic dopamine synthesis capacity in the
striatum and brain stem in the group who subsequently transition to
psychosis versus those who do not (Howes et al., 2011; Allen et al.,
2012). Further longitudinal functional imaging studies are undoubtedly
indicated, nevertheless recent work suggests that this approach may
add predictive power to risk models (Hunter and Lawrie, 2018).
Overall, significant advances have been made in elucidating the
neuroimaging findings indicative of future transition to psychosis. The
predictive accuracy achievable reflects this progress: a balanced accu-
racy of 88% in differentiating between high risk individuals who
transition compared to those who do not has been demonstrated using
sMRI alone, and up to 94% when combined with clinical markers
(Zarogianni et al., 2017). However, thus far studies have been small,
and variability exists between groups. Therefore, a definitive collection
of neuroimaging biomarkers that reliably indicate risk of transition to
psychosis remains to be established (Smieskova et al., 2010;
Lawrie et al., 2011). Future work is likely to focus on optimizing the
accuracy of predictive models by combining neuroimaging biomarkers
with other modalities (S Tognin et al., 2019).
2.3. Genetic biomarkers
The central role of genetics in the etiology of schizophrenia and
psychosis is well established (Gottesman, 1991; Hilker et al., 2018).
Recent years have witnessed a paradigm shift in psychiatric genetics
research towards large consortia led genome wide association studies
(Schizophrenia Working Group of the Psychiatric Genomics
Consortium., 2014; Purcell et al., 2009). These have advanced under-
standing of the polygenic nature of psychiatric disorders, facilitating
the development of polygenic risk scores (PGRS) (Neilson et al., 2018).
PGRS can be applied independently or in conjunction with other bio-
markers to more accurately quantity genetic risk beyond the level of
simple relatedness. One recent study demonstrated elevated polygenic
risk scores for schizophrenia (PGRS-SCZ) in individuals in a familial
high risk cohort who transitioned to schizophrenia, compared to those
who did not (Neilson et al., 2018). Moreover, increased PGRS-SCZ was
found to be significantly associated with increased gyrification within
the frontal lobes bilaterally (Neilson et al., 2018). These promising
early results in this rapidly developing field illustrate the inter-
connectedness of genetic and neuroimaging biomarkers, and suggest
that, in future, they could in combination serve as a clinically useful
predictive tool.
2.4. Multivariate models
Multivariate models of psychosis risk integrate multiple demo-
graphic, clinical, neuroimaging, and genomic findings into potent and
accurate risk prediction tools. Recent multivariate models have shown
accuracy in high risk groups comparable to that of established cardiac,
oncological, and orthopedic risk calculators (Cannon et al., 2016;
Carter et al., 2002; Shah et al., 2012; Cannon et al., 2008).
3. Ethical analysis
Ethical evaluation in the field of predicting psychosis thus far has
predominantly focused on the issues raised by the identification of
clinical high risk groups using symptom scales within a research context
(Corcoran et al., 2005; Mittal et al., 2015; Heinssen et al., 2001;
Morris and Heinssen, 2014; Corcoran, 2016; Lysaght et al., 2012). This
paper furthers existing discussion through in-depth consideration of the
implications of the clinical application of predictive tools, and evalua-
tion of the ramifications of newer multivariate predictive models in-
corporating neuroimaging. The four principles of biomedical ethics are
employed as a conceptual framework for analysis, namely: respect for
autonomy, non-maleficence, beneficence, and justice (Beauchamp and
Childress, 2001).
4. Respect for autonomy
The principle of respect for autonomy requires the clinician to
proactively support individuals in making and acting upon independent
decisions regarding psychosis prediction (Beauchamp and
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Childress, 2001). Autonomy based considerations are particularly
salient at the time of consent for testing and disclosure of results (in-
cluding both intended and incidental findings).
4.1. Informed consent
Informed consent upholds autonomy by safeguarding against med-
ical paternalism. Three components are essential for valid informed
consent: adequate information; capacity to consent; and voluntariness.
We consider how each component can be fulfilled in the context of
psychosis risk prediction.
4.1.1. Adequate information
In the UK, the standard of information disclosure required for
consent has recently changed from that which a responsible body of
clinicians would support disclosing to what a ‘reasonable person in the
patient's position would be likely to attach significance to’ (Bolam v
Friern Hospital Management Committee; Montgomery v Lanarkshire
Health Board; Chan et al., 2017). When deciding whether to undergo
predictive testing for psychosis the ‘reasonable person’ standard is
likely to include, at a minimum, the nature of the condition predicted,
the accuracy of the predictive tool, and the likely costs and benefits of
knowing one's degree of risk (Heinssen et al., 2001; Morris and
Heinssen, 2014). Each of these topics warrants further consideration.
Firstly, the condition predicted is not well defined, as many studies
include a range of different diagnoses with varied treatments and
prognoses under the outcome of psychosis (Hunter and Lawrie, 2018;
Lawrie et al., 2019). Therefore, until such a time when predictive tools
can distinguish between different types of psychotic illness with accu-
racy, the heterogeneity of diagnoses encompassed by this term must be
clearly conveyed, and effort made to avoid the misperception that
psychosis is synonymous with schizophrenia (Heinssen et al., 2001;
Heinimaa and Larsen, 2002; Biesecker and Peay, 2003). In addition,
individuals at high risk for psychosis also have significantly increased
susceptibility to non-psychotic disorders, adding greater complexity to
the meaning of a high risk prediction, which further demands skilled
communication to convey (Lawrie et al., 2019).
Moreover, the ‘reasonable person’ standard demands that informa-
tion be tailored to the individual in question (Chan et al., 2017). Thus,
it is important to take into account variability in pre-existing knowledge
of psychosis. Some individuals may have misperceptions borne of so-
cietal stigma which need debunked through education, whereas others
are likely to be well-informed by virtue of having affected relatives.
Nevertheless, the variability of the same diagnosis between individuals
needs to be communicated (Biesecker and Peay, 2003).
Furthermore, it should be made explicit that predictions are in-
evitably uncertain (Biesecker and Peay, 2003). Clinicians should be
cognizant of the fact that abstract risk predictions can be mis-
interpreted, and time and effort should be afforded to ensuring that the
probabilistic nature of predictions is well understood, to counteract the
tendency to conceptualize risk as a falsely dichotomized prediction that
psychosis will or will not develop (Lysaght et al., 2012; Biesecker and
Peay, 2003).
Lastly, a realistic understanding of the possible benefits and dis-
advantages of learning one's risk status must also be conveyed, with
explicit recognition of where evidence is lacking to ensure the potential
therapeutic gain is not oversold (Heinssen et al., 2001; Heinimaa and
Larsen, 2002). Personal reflection on the psychosocial impact of ob-
taining such knowledge should also be encouraged (Corcoran et al.,
2005; Biesecker and Peay, 2003).
4.1.2. Capacity
Decision-making capacity for predictive testing requires careful
consideration for a number of reasons. Firstly, those at high risk for
psychosis can have significant levels of comorbid psychiatric disorders,
intellectual disabilities, and subthreshold psychotic symptoms, all of
which are potentially (though not inevitably) capacity impairing
(Mittal et al., 2015; Heinssen et al., 2001; Corcoran, 2016; Lawrie et al.,
2019; McGorry et al., 2001). Of note, provision of extra time and ex-
planation has been shown to facilitate capacity in those with estab-
lished schizophrenia, leveling off the disparity with unaffected controls
(Heinssen et al., 2001; Morris and Heinssen, 2014; McGorry et al.,
2001). Therefore, generalized conclusions regarding decision-making
capacity in individuals with mental disorders cannot be drawn, instead
case-by-case assessment in a maximally supportive environment is in-
dicated.
Given the typical age of onset of psychosis, predictive testing is
likely to predominantly target adolescents, raising further questions
surrounding capacity. In the UK, decision-making capacity in minors is
addressed by the concept of Gillick competence, whereby children aged
under 16 years can have capacity to consent, provided they demon-
strate sufficient maturity and intelligence to understand and appraise
the proposed intervention (Gillick v West Norfolk & Wisbech AHA &
DHSS; Wheeler, 2006). For minors deemed not to be Gillick competent
(and adults who lack capacity due to mental illness) questions arise
regarding whether parents or advocates should have the power to give
proxy consent for psychosis prediction, as is generally the case for in-
terventions which are deemed to be in the minor's best interests
(General Medical Council 2018).
In the field of clinical genetics, predictive testing of minors for
adult-onset conditions is contra-indicated, unless interventions in
childhood can prevent or ameliorate illness (Biesecker and Peay, 2003;
Lucassen and Hall, 2019). The ethical reasoning behind this is that al-
lowing a child to make their own decision regarding testing when they
reach adulthood respects their future autonomy and protects their right
to an open future (Feinberg, 1980). In the case of psychosis prediction it
is uncertain whether the therapeutic gain from pre-emptive interven-
tions in childhood or adolescence is compelling enough to justify re-
stricting future autonomy in this manner. Moreover, given the typical
adolescent or early adult onset of psychosis it does not obviously fit the
paradigm of either an adult or childhood-onset condition.
4.1.3. Voluntariness
The final essential component of informed consent is voluntariness.
Individuals at high risk for psychosis may be vulnerable to coercion due
to subthreshold psychotic symptoms, comorbid psychiatric disorders, or
intellectual disability. Persuasion from well-meaning relatives may be
difficult to distinguish from coercion, particularly given this vulner-
ability. Moreover, due to the heritability of psychosis, revealing the risk
status of one individual potentially implicates family members, who
may therefore have personal interests in encouraging or dissuading
testing. In addition, clinicians may harbor unconscious bias in favor of
pursuing risk prediction out of zeal for clinical innovation, and desire to
further understanding of psychosis etiology (Corcoran et al., 2005).
However, screening programs for conditions such as Huntington's Dis-
ease and breast cancer susceptibility illustrate that many people would
rather not know their level of risk (Corcoran et al., 2005; Lawrie et al.,
2012). Thus, individuals must be equally well supported in declining to
undergo predictive testing.
4.2. Disclosure of results
4.2.1. Risk predictions
Respecting autonomy also necessitates disclosing risk predictions in
a manner which is sufficiently explicit to support meaningful decision-
making based on the results, while avoiding engendering hopelessness.
Existing services for those at clinical high risk advocate a ‘hopeful and
competent’ stance in risk disclosure and discussion, whereby the onus is
placed on the treatability and normalization of psychotic disorders
(McGorry et al., 2001). In reality, there is minimal empirical research
examining how individuals react to personal risk predictions and little
to guide how best to disclose predictive information in a manner that
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maximizes autonomy (Biesecker and Peay, 2003).
4.2.2. Incidental findings
In addition to risk prediction results, tools employing neuroimaging
and/or genetic investigations may also give rise to clinically relevant
incidental findings. A recent review demonstrated the presence of in-
cidental findings in 22% of sMRI brain scans obtained in a research
context (O'Sullivan et al., 2018). Fortunately, the majority of incidental
findings on neuroimaging are benign, with further studies indicating
that only 3 to 8% of research MRI scans required onward referral for
further assessment or management of incidental findings
(Katzman et al., 1999; Kim et al., 2002). Of particular note, the rates of
incidental cerebral malignancies are extremely low (O'Sullivan et al.,
2018).
Nevertheless, incidental findings in the context of psychosis pre-
diction have significant implications for informed consent, and results
disclosure. Firstly, in order to facilitate shared decision-making, the
likelihood of incidental findings and their probable clinical significance
should be discussed in advance of the decision to consent for risk pre-
diction (O'Sullivan et al., 2018). Moreover, a patient's right to decline to
be informed about particular clinical findings is a widely accepted tenet
of medical ethics and law, in line with the principle of respect for au-
tonomy (Heinrichs, 2011). However, it is contentious as to whether this
right should extend to the rare instances in which the incidental finding
is life-threatening or comparably risky, as non-disclosure may conse-
quently infringe on the clinician's duty to avoid causing harm
(Heinrichs, 2011).
5. Non-maleficence
The principle of non-maleficence requires the clinician to avoid
causing harm that is disproportionate to the benefits of psychosis risk
prediction (Beauchamp and Childress, 2001). Multiple harms must be
minimized, including: neuroimaging associated risks; stigma; over-
medicalization; misleading results; and threats to data privacy.
5.1. Neuroimaging risks
The neuroimaging modalities employed in current psychosis risk
prediction models are generally well-tolerated. Nevertheless, a number
of associated risks warrant further consideration. Physical risks of MRI
include the displacement or malfunction of implanted medical devices
due to potent magnetic forces; radiofrequency related skin burns; and
noise exposure (European Society of Radiology (ESR) 2019). These risks
can be minimized through detailed patient screening and vigilant ad-
herence to safety precautions (Greenberg and Hoff, 2019). PET scan-
ning has a differing risk profile associated with exposure to radiation,
albeit at low levels, due to the short half-life of radioisotopes ad-
ministered (Downie and Marshall, 2007).
Furthermore, concerns have been voiced regarding the potential for
psychological harms associated with undergoing neuroimaging, espe-
cially MRI. In children and adolescents in particular, scanning has been
linked with anxiety, fear, and distress due to claustrophobia
(Downie and Marshall, 2007; Jaite et al., 2019; Schmidt et al., 2011).
However, such fears have not been substantiated by recent empirical
research, which established similarly low levels of anxiety experienced
during brain MRI by children and adolescents, compared to adult po-
pulations (Jaite et al., 2019).
5.2. Stigma
Sadly, mental illness continues to attract societal stigma, and
identifying individuals as high risk for psychosis may incur similar
negative attitudes (Corcoran et al., 2005; Corcoran, 2016; Sisti and
Calkins, 2016). Stigma exists in a number of forms, including self-
stigma, whereby the individual internalizes negative views, prompting
self-imposed limitations on aspirations (Heinimaa and Larsen, 2002).
Well-meaning family members might discourage the pursuit of longer
term plans such as higher education, and attempt to minimize stress by
prohibiting risk-taking behaviors inherent to personal growth in ado-
lescence (Heinssen et al., 2001; Lawrie et al., 2019; Sisti and
Calkins, 2016). In addition, external discrimination in the form of re-
stricted employment opportunities and curtailed relationships may
occur (Corcoran et al., 2005; Biesecker and Peay, 2003). Moreover, the
stress associated with experiencing stigma may increase risk of pro-
gression to psychosis or schizophrenia (Mittal et al., 2015; Lawrie et al.,
2019). A qualitative study of the attitudes of young people at clinical
high risk for schizophrenia towards predictive genetic testing echoed
concerns that a high risk result could cause them to internalize the ‘sick
role’; face workplace discrimination; and damage relationships
(Lawrence et al., 2016).
However, minimizing stigma requires nuanced consideration, as
evidence suggests that in high risk individuals the overt display of
symptoms of mental illness, as opposed to the high risk label in itself,
generates greater shame and discrimination (Corcoran, 2016). There-
fore, if risk prediction can expedite detection and treatment of psy-
chotic symptoms, it could lessen the overall stigma experienced by the
individual (Corcoran et al., 2005; Mittal et al., 2015; Heinimaa and
Larsen, 2002; McGorry et al., 2001).
5.3. Over-medicalization
Psychosis risk prediction raises challenging questions regarding
what level of susceptibility constitutes high risk and justifies interven-
tion (Heinimaa and Larsen, 2002; Lawrie et al., 2012). Psychosis risk
exists on a spectrum, with no clear boundary demarcating normal from
pathological – thus, labeling people as ‘high risk’ could leave clinicians
open to accusations of over-medicalization, whereby a non-medical
problem is redefined and treated as a disorder (McGorry et al., 2001;
Conrad, 1992).
5.4. Misleading results
Existing ethical discussion is permeated by concern regarding false-
positive results, stemming from findings that approximately two thirds
of those deemed high risk using symptom-based prediction tools do not
transition to psychosis during follow up (Fusar-Poli et al., 2012;
Nelson et al., 2013). These individuals are vulnerable to stigma, over-
medicalization, and intervention side-effects, without possibility of
therapeutic gain. False-negative results could also incur harm through
disincentivizing behavioral change such as avoidance of illicit drug use;
and delaying access to services in the event of symptom onset
(Lawrie et al., 2019; Robinson et al., 2011).
As clinically useful biomarkers emerge focus is shifting towards
individualized risk calculations for psychosis, whereby results are pre-
sented as a probabilistic prediction, rather than a binary assessment of
high risk or not (Lawrie et al., 2019). The issue then evolves from one of
false positives and negatives, to that of predictive power (Heinimaa and
Larsen, 2002). Multivariate models endeavor to deliver a higher pre-
dictive power than tools based on clinical data alone (S Tognin et al.,
2019). Nevertheless, predictions remain approximate, and it is yet to be
established at what threshold of predictive accuracy results are con-
sidered meaningful and useful to individuals.
5.5. Data privacy
The drive towards multivariate prediction models relies on big data
aggregated across centers (Lawrie et al., 2012). Data-sharing raises
questions of how to ensure informed consent for the myriad future uses
of personal data. The concept of broad consent (whereby individuals
are prospectively made aware of the type of data stored; time period for
this; and types of future sharing and use) attempts to balance autonomy
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with recognition of the scientific benefits of allowing future, secondary
use of existing data (Fisher and Layman, 2018).
In addition, skull and cortical imaging, and whole genome se-
quences are potentially identifiable. The threat to anonymity is heigh-
tened when such data is linked, as could be the case in multivariate
prediction models (Lawrie et al., 2019; Fisher and Layman, 2018). The
small body of empirical research available suggests that those at high
risk for psychosis feel apprehensive about information security and
privacy of genetic risk information (Lawrence et al., 2016).
6. Beneficence
In accordance with the principle of beneficence, the benefits of
predictive testing for psychosis should outweigh the risks and costs
(Beauchamp and Childress, 2001). Therefore, ethical analysis requires
evaluation of the prospective gains, including: self-empowerment; early
intervention; potential prevention of transition to psychosis; and en-
hanced prognostication.
6.1. Self-empowerment
Knowledge of one's psychosis risk status can be considered em-
powering, as it enables self-education about psychosis; motivates
avoidance of modifiable risk factors (such as illicit drug use and stress);
facilitates peer support; and heightens self-understanding of subthres-
hold psychotic symptoms (Mittal et al., 2015; Lawrie et al., 2019;
Lawrence et al., 2016). Fore-knowledge also creates a window of op-
portunity to make future wishes known, potentially through an advance
statement, to maximize autonomy in the event of subsequent loss of
capacity through illness (Mittal et al., 2015). Those found to have low
susceptibility could benefit from reassurance in the face of non-psy-
chotic symptoms or a positive family history (Lawrie et al., 2019).
6.2. Early intervention
Moreover, high risk individuals who are predicted to transition to
psychosis could benefit from targeted follow-up to rapidly detect the
onset of psychotic symptoms. The optimal method of delivering such
follow-up is yet to be established, with options ranging from educating
the patient and relatives on early symptoms of psychosis and en-
couraging self-reporting, to the more invasive alternative of regular
contact with an early intervention service (EIS) to monitor mental state.
Minimizing the duration of untreated psychosis (DUP) is associated
with an improvement in clinical and functional outcomes compared to
those who experience treatment delay (Lieberman et al., 2019;
Hegelstad et al., 2012). Nevertheless, a balance should be sought be-
tween facilitating prompt intervention, while avoiding overshadowing
what may be an individual's last pre-symptomatic years with stigma,
anxiety, and medicalization.
Additional benefits of engagement with EIS prior to the onset of
overt psychosis include decreased overall rates of hospital admission,
and a lesser frequency of compulsory admission, compared to patients
with established first episode psychosis (FEP) at initial presentation
(Valmaggia et al., 2015). Furthermore, ongoing management in an EIS
setting has been demonstrated to result in lesser treatment dis-
continuation, lesser disruption to education and employment, and
lower symptom severity at the end of the treatment course, compared
with treatment out with a specialized service (Correll et al., 2018). In
addition, the collaborative, individualized approach adopted by EIS
teams is valued by patients and families (Lester et al., 2011; Lavis et al.,
2015). Nevertheless, these prospective benefits are presented with the
caveat that the evidence base for many interventions typically delivered
as part of the EIS model, such as phase-specific cognitive behavioral
therapy (CBT) and family therapy in FEP is lacking, and subsequent
trials are indicated (Marshall and Rathbone, 2011). Moreover, a
number of studies indicate that the improved clinical and functional
outcomes associated with EIS are not sustained in the longer term,
particularly following discharge back to generic psychiatric care
(Chang et al., 2017; Gafoor et al., 2010; Bertelsen et al., 2008).
6.3. Preventing transition
The ultimate ambition of prevention research is to avert (or delay)
the development of psychosis. Currently, no specific intervention has a
robust evidence base as a primary prevention agent for those at high
risk (Lieberman et al., 2019; Stafford et al., 2013; Kuharic et al., 2019).
Nevertheless, CBT has been demonstrated to reduce transition to psy-
chosis (both alone and in conjunction with family intervention), how-
ever the evidence in support of this is admittedly of variable quality
(Stafford et al., 2013; Kuharic et al., 2019). Similarly, integrated psy-
chotherapy shows an association with preventing transition, with the
caveat of a low quality evidence base (Stafford et al., 2013). Lastly, one
small study suggests that omega-3 fatty acids may prevent psychosis,
however this effect has not been well-replicated (Stafford et al., 2013;
Kuharic et al., 2019). Contrastingly, antipsychotic medications have
shown little efficacy in primary prevention (Stafford et al., 2013;
Kuharic et al., 2019). Overall, while a number of interventions show
early promise, more methodologically robust, larger studies are in-
dicated to provide a reliable evidence base regarding the efficacy of
primary prevention for those at high risk of psychosis.
In addition to efficacy, interventions must prove acceptable to in-
dividuals in terms of side-effect profile (Heinimaa and Larsen, 2002).
This is particularly problematic in the case of antipsychotics, with
short-term considerations such as extrapyramidal side effects, hyper-
prolactinemia, sedation, and weight gain, and longer term potential
consequences of tardive dyskinesia, diabetes and cardiovascular disease
(Corcoran et al., 2005; Heinssen et al., 2001; Sisti and Calkins, 2016).
Moreover, the lack of clinical trials of antipsychotic use in the sensitive
developmental period of adolescence adds an element of uncertainty to
the potential long-term effects (Heinimaa and Larsen, 2002). Alter-
natives to antipsychotics, such as CBT and omega-3 fatty acids have
more palatable risk profiles (Corcoran et al., 2005; Mittal et al., 2015).
6.4. Prognostication and targeted intervention
In recent years, research on those at high risk of psychosis has
broadened in scope beyond predicting transition, to investigate neu-
roimaging biomarkers associated with other salient outcomes in this
cohort, such as social and occupational functioning (Koutsouleris et al.,
2018). Functional outcomes are deemed particularly significant in this
cohort, as the high risk state can be associated with neurocognitive and
functional deficits. These can have marked personal and socioeconomic
implications, even among individuals who do not transition to psy-
chosis. One study utilizing baseline sMRI in a high risk group evidenced
lower gray matter density in bilateral frontal and limbic areas, and left
cerebellar declive, in association with poorer functional outcomes at
medium to long-term follow-up, independent of transition to psychosis
(Reniers et al., 2016). Furthermore, machine learning models com-
bining baseline neuroimaging and clinical findings have demonstrated
the ability to predict impaired social functioning at 1-year follow-up
correctly in up to 83% of individuals in a high risk cohort, thus out-
performing human prognostication (Koutsouleris et al., 2018). The
ability to reliably predict which high risk individuals are likely to ex-
perience functional impairment could facilitate targeted psychosocial
support at an early stage, with the aim of averting poor outcomes
(Reniers et al., 2016).
7. Justice
Justice demands that the benefits, costs and risks of predictive
testing for psychosis are distributed fairly among individuals, such that
no-one is unduly advantaged or disadvantaged by this intervention
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(Beauchamp and Childress, 2001). Ensuring parity in the context of a
publicly funded health service with finite resources requires predictive
testing be cost-effective; equally accessible to all; and delivered in a
manner that avoids reinforcing structural biases.
7.1. Cost-effectiveness
Cost is a core consideration when implementing screening pro-
grams. Predicting transition to psychosis holds the potential to deliver
cost savings by enabling early intervention and its associated improved
outcomes. EIS has been shown to be cheaper than non-specialist com-
munity mental health teams when assessing direct cost to the NHS,
largely via reduced length of mental health inpatient admissions
(Tsiachristas et al., 2016). When the wider societal cost of illness is
considered greater savings could be achieved. A systematic review
identified evidence in support of the cost effectiveness of EIS, however
the authors commented that the evidence base remains relatively small
and heterogenous, thus identifying a need for further well-constructed
studies (Aceituno et al., 2019).
Furthermore, the expense of investigations involved in psychosis
risk calculation, such as neuroimaging, must also be factored into cost-
effectiveness analyses. Recent research indicates that the use of stan-
dard sMRI with the indication of ruling out treatable organic causes in
patients presenting with FEP is not financially viable, despite this
modality being relatively widely available (Tsiachristas et al., 2016;
Valmaggia et al., 2009). However, this finding cannot necessarily be
generalized to the case of psychosis risk prediction. Other potentially
useful neuroimaging modalities in prediction, such as PET, remain
comparatively inaccessible and prohibitively expensive (Abi-
Dargham and Horga, 2016). Overall, there is a paucity of data re-
garding the cost-effectiveness of neuroimaging and other resources,
necessary for the clinical implementation of psychosis susceptibility
screening.
7.2. Equity of access
Currently, the neuroimaging and genomics capabilities required for
multivariate models of psychosis risk are largely isolated to research
centers in developed countries (Lawrie et al., 2019; Corsico, 2019). In
the meantime, the design of adapted versions of predictive tools ex-
cluding less widespread modalities could help widen access to screening
(Lawrie et al., 2012).
The task of accessing high risk individuals to offer predictive testing
poses a further challenge to distributive justice. The majority of those
who develop schizophrenia are not obviously at high familial or cog-
nitive risk (Lawrie et al., 2012). Moreover, given the prevalence of
subthreshold psychotic symptoms in this group, high risk individuals
may be particularly difficult to engage due to social withdrawal, decline
in functioning, and poor insight (McEvoy et al., 2006; Gronholm et al.,
2017). The stigma associated with mental health services poses another
significant barrier to service engagement, leading to widespread efforts
to ensure that prodromal psychosis services are discretely named and
located in neutral, community spaces (Corcoran et al., 2005;
Heinssen et al., 2001; McGorry et al., 2001; Norman et al., 2004).
Existing prodromal psychosis services proactively encourage re-
ferral of potentially high risk individuals through links with primary
care; emergency services; and non-clinical community services (e.g.
schools and criminal justice agencies) (Ajnakina et al., 2017). Despite
this, a recent study of one UK trust found that only 4.1% of those with
FEP had previously engaged with prodromal services (Ajnakina et al.,
2017). Therefore, even if accurate prediction and effective preventative
interventions were a clinical reality, targeting the population currently
served by prodromal services would avert few instances of transition to
psychosis. Moreover, concerns were raised regarding inequality in ac-
cess to prodromal services as 77% of referrals were received from GPs
and healthcare workers, potentially disadvantaging those who are less
likely to be registered with a GP, such as migrants (Ajnakina et al.,
2017). Previous studies have found further disparities in access to ser-
vices, including an association between greater geographical distance
from service location and longer DUP (Kvig et al., 2017).
7.3. Algorithmic bias
Machine learning has the potential, if reliably calibrated, to reduce
the impact of clinical bias in healthcare (Martinez-Martin et al., 2018).
However, machine learning algorithms could equally reinforce existing
structural biases depending upon how they account for factors such as
socioeconomic status and race (Corsico, 2019; Martinez-Martin et al.,
2018). The influence of such biases in existing psychiatric diagnostic
practice has been widely discussed (Schwartz and Blankenship, 2014).
Heightened concerns arise due to the perceived lack of transparency in
machine learning, whereby it is possible for neither the clinician nor the
patient to be aware of the how the prediction is generated, thus pre-
cluding questioning of it. This could curtail shared decision-making and
impede trust. Clinicians employing machine learning in psychosis pre-
diction should be well-informed regarding how the algorithm is de-
veloped; the data on which it is based; and its limitations, in order to
critically appraise its outcomes (Martinez-Martin et al., 2018).
8. Conclusion
The rapidly developing field of psychosis prediction holds promise
of meaningfully improving clinical outcomes for those at high risk of
psychosis. Structural and functional neuroimaging has a central role in
optimizing the predictive power of current risk models. However, it is
imperative that such scientific innovation proceeds in tandem with
ethical consideration. This paper furthers existing ethical discussion by
considering the ramifications of the clinical application of predictive
tools, and evaluating the ethical implications of newer risk models in-
corporating neuroimaging. Ethical priorities include, firstly, ensuring
predictive testing is carried out in a manner which promotes autonomy
through valid informed consent, and meaningful disclosure of results.
Secondly, minimizing the risks of neuroimaging, stigma, over-medica-
lization, misleading results, and compromised data privacy. Thirdly,
promoting the prospective benefits of early intervention; avoidance of
modifiable risk factors; heightened understanding of subthreshold
psychotic experiences; access to education and peer support; opportu-
nity for advanced planning; and enhanced prognostication. Finally,
upholding distributive justice by ensuring cost-effectiveness; facilitating
equal access to testing; and avoiding reinforcement of structural biases.
Empirical study of the views of those who have most at stake in pre-
dictive testing, namely high risk individuals and their families, is cru-
cial to achieving these aims. Ultimately, continued scientific progress
alongside empirically informed ethical analysis will allow us to preempt
adverse effects and maximize the great potential benefits of predictive
testing for individuals at high risk of psychosis.
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